These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38981102)

  • 1. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):105-112. PubMed ID: 38981102
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1602):105-112. PubMed ID: 32728009
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison table: Some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):e112-e114. PubMed ID: 38981103
    [No Abstract]   [Full Text] [Related]  

  • 4. Romosozumab (Evenity) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):83-86. PubMed ID: 31170119
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1546):e112-e114. PubMed ID: 32728010
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
    Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.